Gil Pogozelich
Chairman
Claimed by owner DiaGyn
Former names:
Targeted Chemotherapy for Breast and Ovarian Cancer
DiaGyn
About
DiaGyn is developing a wide range of solutions targeting unmet needs in the area of womens health, integrating drug development and molecular genomics with personalized therapeutic approaches. The company is focused on addressing BRCA1/2 mutations in ovarian and breast cancer using a treatment strategy based on nanoparticle technology.
DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). The innovative product comprises 100 nm mesoporous silica nanoparticles (MSNP) loaded with the antineoplastic docetaxel and capped with the cyclic oligosaccharide cyclodextrin. The cyclodextrin cap linked to the silica particles prevents the uncontrolled release of chemotherapy from the pores before arrival at the intended site.
The special design of DiaGyns nanoparticles involves a sensitive linker that selectively senses the high levels of -galactosidase and low pH encountered in the surrounding EOC cells, releasing the drug into the malignant cells while leaving normal tissues largely unaffected.
DiaGyn is a subsidiary of Goldman Hirsh Partners.
DiaGyn has developed DIG790 for the treatment of patients with advanced epithelial ovarian cancer (EOC). The innovative product comprises 100 nm mesoporous silica nanoparticles (MSNP) loaded with the antineoplastic docetaxel and capped with the cyclic oligosaccharide cyclodextrin. The cyclodextrin cap linked to the silica particles prevents the uncontrolled release of chemotherapy from the pores before arrival at the intended site.
The special design of DiaGyns nanoparticles involves a sensitive linker that selectively senses the high levels of -galactosidase and low pH encountered in the surrounding EOC cells, releasing the drug into the malignant cells while leaving normal tissues largely unaffected.
DiaGyn is a subsidiary of Goldman Hirsh Partners.
Primary Sector
Life Sciences & HealthTech
Products
DIG790
Geographic markets
Global
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
0
Investors
0
News
(0)The Team
(3)
GP
DI
Diana Ickowicz
CEO
RF
Roy Farfara
Co-founder
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Media gallery
(0)Locations
Israel
Abba Eban Ave 1, Herzliya, Israel
Locations
Israel
Abba Eban Ave 1, Herzliya, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,